by GlyTherix | Feb 22, 2024
GlyTherix is pleased to announce Dr Brad Walsh will be presenting the GlyTherix Ltd story at 1.15pm on Friday March 1 at the B. Riley Securities Radiopharma Day. Email radiopharma@brileyfin.com for more...
by GlyTherix | Feb 21, 2024
GlyTherix Ltd is pleased to announce Alan Harris MD PhD has taken an expanded role as a Strategic and Scientific Advisor to assist the company increase its current US footprint including retention of key US-based personnel. He will work closely with GlyTherix’s Dr...
by GlyTherix | Feb 16, 2024
GlyTherix Ltd is pleased to advise it has appointed Atoll Financial Group as its financial advisor for its Series B raise of up to USD50M. This round will enable the company to push forward its targeted radiotherapy program Phase 1b trial and includes funding for its...
by GlyTherix | Jan 8, 2024
GlyTherix Ltd is so pleased to announce another esteemed clinician has joined our advisory board. Elcin Zan, MD is a dual board-certified radiologist specializing in Nuclear Medicine and Neuroradiology. She is an Assistant Professor of Clinical Radiology at Weill...
by GlyTherix | Jan 7, 2024
Meet us at J.P. Morgan between January 8 and 11 in San Francisco, CA. We are so pleased to have an awesome team from GlyTherix with us in San Francisco. It is the perfect time to get involved with us as the targeted radiotherapy field keeps going from strength to...
by GlyTherix | Dec 15, 2023
We are excited to welcome Dr Alan Harris to our Advisory Board. Dr Harris comes with a long history of success in the radiopharmaceutical space as a researcher, commercializer and businessman (see here). The company has been guided by Alan during the first phase of...
